Investment & Fund Management
BMEYE secured expert advice and financial backing from several venture capital
Full Credential Description
BMEYE B.V., a Dutch company based in Amsterdam, specializes in developing and selling advanced cardiac monitoring devices. The company faced significant challenges in bringing its latest technology, the Nexfin®, to market. This device offers non-invasive, continuous monitoring of blood pressure and cardiac output using a simple finger cuff, which is crucial for rapid diagnosis in emergency medical situations. However, BMEYE required assistance with regulatory registration and approval from food and drug authorities, as well as support for the commercialization and distribution of the device.
In late 2009, BMEYE secured expert advice and financial backing from several venture capital fund managers, including 360 Capital Partners, which provided EUR 2 million through the Competitiveness and Innovation Framework Programme (CIP). This funding enabled BMEYE to hire 11 new staff members, obtain the necessary regulatory clearances, and gather sufficient clinical evidence to launch Nexfin® commercially. As a result, the device is now utilized in emergency and intermediate care units, operating rooms, and recovery rooms, with potential applications in various other medical fields, significantly expanding its market reach. The innovative technology of Nexfin® also earned BMEYE recognition as one of the 2010 Red Herring 100 companies, highlighting its impact and success in the cardiovascular monitoring industry.